

## CR&T Funded Publications

Publications are continually being updated,  
check back often for updates.



[Reem S. Chamseddine, Oleksandr Savenkov, Shehroz Rana, Mohammed Khalid, Richard T. Silver, Nicole Kucine, Joseph M. Scandura, Ghaith Abu-Zeinah; Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. \*Blood Adv\* 2024; 8 \(10\): 2520–2526. doi: <https://doi.org/10.1182/bloodadvances.2023012459>](#)

Abu-Zeinah, G., Erdos, K., Lee, N., Lebbe, A., Bouhali, I., Khalid, M., Silver, R., & Scandura, J. (2024). Are thrombosis, progression, and survival in ET predictable? *Blood Cancer Journal*.

[Silver, R.T., Erdos, K., Taylor, E. et al. Splenomegaly \(SPML\) in polycythemia vera \(PV\): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis \(PPMF\) and survival. \*Leukemia\* 37, 691–694 \(2023\). <https://doi.org/10.1038/s41375-022-01793-w>](#)

[Silver, R. T., & Abu-Zeinah, G. \(2023\). Polycythemia vera: aspects of its current diagnosis and initial treatment. \*Expert Review of Hematology\*, 16\(4\), 253–266. <https://doi.org/10.1080/17474086.2023.2198698>](#)

[Abu-Zeinah, G., Tokumori, F. G., Erdos, K., Bouhali, I., Choi, D., Silver, R., Scandura J. \(2022, December 11\) Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival \[Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II\]. American Society of Hematology Annual Meeting & Exposition, San Diego, CA, USA](#)

[Daniel C Choi, Ghaith Abu-Zeinah, Silvana Di Giandomenico, Katie Erdos, Joseph Scandura; JAK2<sup>V617F</sup> Impairs T Cell Differentiation in Polycythemia Vera. \*Blood\* 2022; 140 \(Supplement 1\): 6746–6747. doi: <https://doi.org/10.1182/blood-2022-167785>](#)

[Reem S. Chamseddine, Shehroz Rana, Mohammed Khalid, Nicole Kucine, Richard T. Silver, Joseph Scandura, Ghaith Abu-Zeinah; Safety of Cytoreductive Therapy in Younger Patients with Polycythemia Vera: A Systematic Review and Meta-Analysis. \*Blood\* 2022; 140 \(Supplement 1\): 3999–4000. doi: <https://doi.org/10.1182/blood-2022-168014>](#)

[Franco Castillo Tokumori, Joseph Scandura, Ghaith Abu-Zeinah; Polycythemia Vera Molecular Response and Its Correlation with Disease Progression: A Systematic Review and Meta-Analysis. Blood 2022; 140 \(Supplement 1\): 3993–3994. doi: <https://doi.org/10.1182/blood-2022-170731>](#)

[Ghaith Abu-Zeinah, Spencer Krichevsky, Katie Erdos, Richard T. Silver, Joseph Scandura; Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera \(PV\) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV. Blood 2022; 140 \(Supplement 1\): 3961–3962. doi: <https://doi.org/10.1182/blood-2022-170893>](#)

[Mora B, Maffioli M, Rumi E, Guglielmelli P, Caramella M, Kuykendall A, et al. Incidence of blast phase in myelofibrosis according to anemia severity. eJHaem. 2023; 4: 679–689. <https://doi.org/10.1002/jha2.745>](#)